; or (C) is developed in a State that has notified the Secretary of Health and Human Services of its intention to review tests intended to diagnose COVID-19. (2) Items and services furnished to an individual during health care provider office visits, urgent care center visits, and emergency room visits that result in an order for or administration of an in vitro diagnostic product described in paragraph (1), but only to the extent such items and services relate to the furnishing or administration of such product or to the evaluation of such individual for purposes of determining the need of such individual for such product. 4202. Pricing of diagnostic testing (a) Reimbursement rates A group health plan or a health insurance issuer providing coverage of items and services described in section 201(a) with respect to an enrollee shall reimburse the provider of the diagnostic testing as follows: (1) If the health plan or issuer has a negotiated rate for such service with such provider, such negotiated rate shall apply. (2) If the health plan or issuer does not have a negotiated rate for such service with such provider, such plan or issuer shall reimburse the provider in an amount that equals the cash price for such service as listed by the provider on a public internet website. (b) Requirement to Publicize Cash Price for Diagnostic Testing for COVID-19 (1) In general Each provider of a diagnostic test for COVID-19 shall make public the cash price for such test on a public internet website of such provider. (2) Civil monetary penalties The Secretary of Health and Human Services may impose a civil monetary penalty on any provider of a diagnostic test for COVID-19 that is not in compliance with paragraph (1) and has not completed a corrective action plan to comply with the requirements of such paragraph, in an amount not to exceed $300 per day that the violation is ongoing. 4203. Rapid coverage of preventive services and vaccines for coronavirus (a) In general Notwithstanding 2713(b) of the Public Health Service Act (